NASDAQ:ANIK - Anika Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.00
  • Forecasted Upside: 17.17 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$36.70
▼ -0.69 (-1.85%)
1 month | 3 months | 12 months
Get New Anika Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANIK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$43.00
▲ +17.17% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Anika Therapeutics in the last 3 months. The average price target is $43.00, with a high forecast of $43.00 and a low forecast of $43.00. The average price target represents a 17.17% upside from the last price of $36.70.
Buy
The current consensus among 1 polled investment analysts is to buy stock in Anika Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2019
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/6/2019
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/5/2020
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/3/2020
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/1/2020
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/16/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$43.00High
i
Rating by M. Petusky at Barrington Research
5/8/2020Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Petusky at Barrington Research
2/21/2020Barrington ResearchReiterated RatingBuy$60.00Low
i
Rating by Michael Petusky at Barrington Research
1/21/2020SidotiUpgradeNeutral ➝ Buy$61.00Low
i
Rating by James Sidoti at Sidoti
1/10/2020First AnalysisUpgradeOutperform ➝ Strong-Buy$65.00Low
i
Rating by Joseph Munda at First Analysis
11/5/2019BWS FinancialInitiated CoverageSell$29.00High
i
Rating by H. Khorsand at BWS Financial
10/25/2019SidotiSet Price TargetHold$50.00N/A
i
Rating by James Sidoti at Sidoti
9/24/2019Barrington ResearchReiterated RatingOutperform$49.00 ➝ $58.00Medium
i
9/23/2019First AnalysisDowngradeStrong-Buy ➝ Outperform$54.00Low
i
7/25/2019Barrington ResearchReiterated RatingBuy$45.00 ➝ $49.00High
i
7/25/2019First AnalysisUpgradeNeutral ➝ Strong-Buy$37.00 ➝ $54.00High
i
3/5/2019SidotiSet Price TargetHold$35.00Low
i
Rating by James Sidoti at Sidoti
2/28/2019Singular ResearchReiterated RatingBuyMedium
i
Rating by L. Springer at Singular Research
2/22/2019Barrington ResearchLower Price TargetOutperform$44.00High
i
2/22/2019SidotiDowngradeBuy ➝ Neutral$56.00 ➝ $41.00High
i
2/22/2019First AnalysisDowngradeOutperform ➝ Neutral$41.00 ➝ $37.00High
i
7/27/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$48.00Medium
i
Rating by M. Petusky at Barrington Research
6/20/2018Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Petusky at Barrington Research
6/20/2018First AnalysisDowngradeOverweight ➝ Equal Weight$45.00 ➝ $34.00High
i
Rating by Joseph Munda at First Analysis
5/4/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$39.00High
i
Rating by M. Petusky at Barrington Research
2/23/2018Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Petusky at Barrington Research
1/26/2018SidotiInitiated CoverageBuyLow
i
1/24/2018First AnalysisUpgradeEqual Weight ➝ Overweight$45.00 ➝ $68.00High
i
12/28/2017Barrington ResearchReiterated RatingBuy$57.00Low
i
10/27/2017Barrington ResearchBoost Price TargetOutperform ➝ Outperform$53.00 ➝ $57.00N/A
i
4/27/2016Northland SecuritiesDowngradeOutperform ➝ Market PerformN/A
i
(Data available from 3/1/2016 forward)
Anika Therapeutics logo
Anika Therapeutics, Inc., together with its subsidiaries, operates as an integrated joint preservation, restoration, and regenerative solutions company in the United States, Europe, and internationally. The company's lead products include HYALOMATRIX for the treatment of skin wounds, such as pressure ulcers, diabetic foot ulcers, and deep second-degree burns; and MEROGEL, a woven fleece nasal packing. Its joint pain management products comprise MONOVISC, ORTHOVISC, and CINGAL that are used as hyaluronic acid (HA) based viscosupplements to treat osteoarthritis pain in humans; and HYVISC, a HA-based treatment for equine osteoarthritis pain. In addition, the company offers HYALOFAST, a HYAFF-based support for human bone marrow mesenchymal stem cells used for cartilage regeneration and adjunct for microfracture surgery; and Tactoset, a HA-enhanced bone repair therapy to treat insufficiency fractures. Further, it provides ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; joint surface implant and preservation solutions for knee, shoulder, hip, ankle, wrist, and toe to treat upper and lower orthopedic conditions caused by trauma, injury, and arthritic disease; and surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $36.70
$36.70
$38.03

50 Day Range

MA: $38.25
$35.47
$42.86

52 Week Range

Now: $36.70
$22.01
$47.47

Volume

2,689 shs

Average Volume

119,526 shs

Market Capitalization

$521.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Anika Therapeutics?

The following Wall Street research analysts have issued reports on Anika Therapeutics in the last year: Barrington Research, and Zacks Investment Research.
View the latest analyst ratings for ANIK.

What is the current price target for Anika Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Anika Therapeutics in the last year. Their average twelve-month price target is $43.00, suggesting a possible upside of 17.2%. Barrington Research has the highest price target set, predicting ANIK will reach $43.00 in the next twelve months. Barrington Research has the lowest price target set, forecasting a price of $43.00 for Anika Therapeutics in the next year.
View the latest price targets for ANIK.

What is the current consensus analyst rating for Anika Therapeutics?

Anika Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANIK will outperform the market and that investors should add to their positions of Anika Therapeutics.
View the latest ratings for ANIK.

What other companies compete with Anika Therapeutics?

How do I contact Anika Therapeutics' investor relations team?

Anika Therapeutics' physical mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company's listed phone number is 781-457-9000 and its investor relations email address is [email protected] The official website for Anika Therapeutics is www.anikatherapeutics.com.